| pubmed-article:16760927 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16760927 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:16760927 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:16760927 | lifeskim:mentions | umls-concept:C0011570 | lld:lifeskim |
| pubmed-article:16760927 | lifeskim:mentions | umls-concept:C0073393 | lld:lifeskim |
| pubmed-article:16760927 | lifeskim:mentions | umls-concept:C1293122 | lld:lifeskim |
| pubmed-article:16760927 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:16760927 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:16760927 | lifeskim:mentions | umls-concept:C0332283 | lld:lifeskim |
| pubmed-article:16760927 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:16760927 | pubmed:dateCreated | 2006-10-18 | lld:pubmed |
| pubmed-article:16760927 | pubmed:abstractText | Approximately one-third of persons with depression do not respond to antidepressant monotherapy. Studies suggest that atypical antipsychotic augmentation may benefit these patients. We investigated the longer-term efficacy of risperidone augmentation of serotonin-selective reuptake inhibitor treatment for resistant depression. In 57 in- and outpatient centers in three countries, we conducted a three-phase study with 4-6 weeks of open-label citalopram monotherapy, 4-6 weeks of open-label risperidone augmentation, and a 24-week double-blind, placebo-controlled discontinuation phase. A total of 489 patients with major depressive disorder and 1-3 documented treatment failures entered the citalopram monotherapy phase (20-60 mg/day). Patients with <50% reduction in HAM-D-17 scores entered the risperidone augmentation phase (0.25-2.0 mg/day). Patients with HAM-D-17< or =7 or CGI-S < or = 2 were randomized to risperidone or placebo augmentation. The primary outcome was time to relapse during the double-blind phase. During citalopram monotherapy, 434 patients had <50% HAM-D-17 reduction; 299 (68.9%) were fully nonresponsive (<25% reduction) and 135 were partially nonresponsive (25-49% reduction). Of the 386 nonresponders who entered the augmentation phase, 243 remitted and 241 entered the double-blind phase. Median time to relapse was 102 days with risperidone augmentation and 85 days with placebo (NS); relapse rates were 53.3 and 54.6%, respectively. In a post hoc analysis of patients fully nonresponsive to citalopram monotherapy, median time to relapse was 97 days with risperidone augmentation and 56 with placebo (p = 0.05); relapse rates were 56.1 and 64.1%, respectively (p < or = 0.05). Open-label risperidone augmentation substantially enhanced response in treatment-resistant patients, but the longer-term benefits of augmentation were not demonstrated in this study. | lld:pubmed |
| pubmed-article:16760927 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16760927 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16760927 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16760927 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16760927 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16760927 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16760927 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16760927 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16760927 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16760927 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16760927 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16760927 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16760927 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16760927 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16760927 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:16760927 | pubmed:issn | 0893-133X | lld:pubmed |
| pubmed-article:16760927 | pubmed:author | pubmed-author:MahmoudRamy... | lld:pubmed |
| pubmed-article:16760927 | pubmed:author | pubmed-author:NemeroffCharl... | lld:pubmed |
| pubmed-article:16760927 | pubmed:author | pubmed-author:KellerMartin... | lld:pubmed |
| pubmed-article:16760927 | pubmed:author | pubmed-author:RapaportMark... | lld:pubmed |
| pubmed-article:16760927 | pubmed:author | pubmed-author:BouhoursPhili... | lld:pubmed |
| pubmed-article:16760927 | pubmed:author | pubmed-author:CanusoCarla... | lld:pubmed |
| pubmed-article:16760927 | pubmed:author | pubmed-author:LasserRobert... | lld:pubmed |
| pubmed-article:16760927 | pubmed:author | pubmed-author:TurkozIbrahim... | lld:pubmed |
| pubmed-article:16760927 | pubmed:author | pubmed-author:BossieCynthia... | lld:pubmed |
| pubmed-article:16760927 | pubmed:author | pubmed-author:GharabawiGeor... | lld:pubmed |
| pubmed-article:16760927 | pubmed:author | pubmed-author:DunbarFionaF | lld:pubmed |
| pubmed-article:16760927 | pubmed:author | pubmed-author:LoescherAmyA | lld:pubmed |
| pubmed-article:16760927 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16760927 | pubmed:volume | 31 | lld:pubmed |
| pubmed-article:16760927 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16760927 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16760927 | pubmed:pagination | 2505-13 | lld:pubmed |
| pubmed-article:16760927 | pubmed:dateRevised | 2011-5-18 | lld:pubmed |
| pubmed-article:16760927 | pubmed:meshHeading | pubmed-meshheading:16760927... | lld:pubmed |
| pubmed-article:16760927 | pubmed:meshHeading | pubmed-meshheading:16760927... | lld:pubmed |
| pubmed-article:16760927 | pubmed:meshHeading | pubmed-meshheading:16760927... | lld:pubmed |
| pubmed-article:16760927 | pubmed:meshHeading | pubmed-meshheading:16760927... | lld:pubmed |
| pubmed-article:16760927 | pubmed:meshHeading | pubmed-meshheading:16760927... | lld:pubmed |
| pubmed-article:16760927 | pubmed:meshHeading | pubmed-meshheading:16760927... | lld:pubmed |
| pubmed-article:16760927 | pubmed:meshHeading | pubmed-meshheading:16760927... | lld:pubmed |
| pubmed-article:16760927 | pubmed:meshHeading | pubmed-meshheading:16760927... | lld:pubmed |
| pubmed-article:16760927 | pubmed:meshHeading | pubmed-meshheading:16760927... | lld:pubmed |
| pubmed-article:16760927 | pubmed:meshHeading | pubmed-meshheading:16760927... | lld:pubmed |
| pubmed-article:16760927 | pubmed:meshHeading | pubmed-meshheading:16760927... | lld:pubmed |
| pubmed-article:16760927 | pubmed:meshHeading | pubmed-meshheading:16760927... | lld:pubmed |
| pubmed-article:16760927 | pubmed:meshHeading | pubmed-meshheading:16760927... | lld:pubmed |
| pubmed-article:16760927 | pubmed:meshHeading | pubmed-meshheading:16760927... | lld:pubmed |
| pubmed-article:16760927 | pubmed:meshHeading | pubmed-meshheading:16760927... | lld:pubmed |
| pubmed-article:16760927 | pubmed:meshHeading | pubmed-meshheading:16760927... | lld:pubmed |
| pubmed-article:16760927 | pubmed:meshHeading | pubmed-meshheading:16760927... | lld:pubmed |
| pubmed-article:16760927 | pubmed:meshHeading | pubmed-meshheading:16760927... | lld:pubmed |
| pubmed-article:16760927 | pubmed:meshHeading | pubmed-meshheading:16760927... | lld:pubmed |
| pubmed-article:16760927 | pubmed:meshHeading | pubmed-meshheading:16760927... | lld:pubmed |
| pubmed-article:16760927 | pubmed:meshHeading | pubmed-meshheading:16760927... | lld:pubmed |
| pubmed-article:16760927 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16760927 | pubmed:articleTitle | Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation. | lld:pubmed |
| pubmed-article:16760927 | pubmed:affiliation | Department of Psychiatry, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. mark.rapaport@cshs.org | lld:pubmed |
| pubmed-article:16760927 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16760927 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:16760927 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:16760927 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:16760927 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16760927 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16760927 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16760927 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16760927 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16760927 | lld:pubmed |
